ClinicalTrials.gg

Program

ribitol

Also written as “BBP-418 (ribitol)” and “BBP-418”.

Its studies are mostly in Muscular Dystrophies, Limb-Girdle, led by BridgeBio.

Furthest: phase 3, since Feb 16, 20233 company-led studies, 3 open or runningNext primary completion: Sep 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BridgeBio33 open or runningphase 3since Feb 16, 2023Jan 25, 2021Sep 2027phase 3 · NCT05775848

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 25, 2021First study: phase 2 study in Muscular Dystrophy, Limb-Girdle, Type 2IFirst studyNCT04800874 · 14 enrolled · United States
  2. Feb 16, 2023Phase 3 study in Muscular Dystrophy, Limb-Girdle, Type 2INCT05775848 · 112 enrolled · United States, Australia, Denmark and more
  3. Jun 25, 2026Phase 3 study in Muscular Dystrophy, Limb-Girdle, Type 2INCT07678775 · 107 enrolled · United States, Australia, Denmark and more

Ahead

  1. Nov 1, 2026Primary completion: phase 2 study in Muscular Dystrophy, Limb-Girdle, Type 2INCT04800874
  2. Sep 2027Primary completion: phase 3 study in Muscular Dystrophy, Limb-Girdle, Type 2INCT05775848
  3. Oct 2030Primary completion: phase 3 study in Muscular Dystrophy, Limb-Girdle, Type 2INCT07678775

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07678775Muscular Dystrophy, Limb-Girdle, Type 2I · United States, Australia, Denmark and more3Active, not recruitingOct 2030107
NCT05775848Muscular Dystrophy, Limb-Girdle, Type 2I · United States, Australia, Denmark and more3Active, not recruitingSep 2027112
NCT04800874Muscular Dystrophy, Limb-Girdle, Type 2I · United States2Active, not recruitingNov 1, 202614

How it is read

Names in the registry

  • “BBP-418 (ribitol)”, 2 entries
  • “BBP-418”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.